Springe zum Inhalt

Foundation Fighting Blindness stellt die Top 10 Therapieoption vor

Unter top 4 ist Ataluren bei Nonsene Mutationen aufgeführt.
Die Kanadische Forscherin Gregory-Evans führt derzeit die Aniridia Studie durch.

DRUG THERAPIES
Scientists are working to identify and develop new drug with the capacity to preserve remaining vision and prevent further vision loss. In 2016, three FFB-funded researchers made critical steps toward making new drug therapies for blinding eye diseases a reality.

4. Dr. Cheryl Gregory-Evans is developing a drug that would address one type of disease-causing mutation, known as a “nonsense” mutation, which is responsible for approximately 35% of all cases of Leber congenital amaurosis (LCA). Nonsense mutations cause premature stop signs, which lead to non-functional proteins. The absence of these necessary proteins cause disease. Dr. Gregory-Evans is pioneering a nonsense read-through therapy, which uses drugs that allow the cellular machinery to ignore the incorrect stop sign and produce full-length, functional proteins. This year, her team made key progress with their discovery that if the drugs are given early enough then the retina can be preserved. This positive data with their work on LCA means that they can test this drug combination approach for other retinal diseases!

Top 10 Discoveries Driving the Race to Restore Sight in 2016

Schreibe einen Kommentar

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind mit * markiert

I accept that my given data and my IP address is sent to a server in the USA only for the purpose of spam prevention through the Akismet program.More information on Akismet and GDPR.

Diese Website verwendet Akismet, um Spam zu reduzieren. Erfahre mehr darüber, wie deine Kommentardaten verarbeitet werden.